Patent ID: 11911459
Assignee: IMMUNITYBIO, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 16:
17. A method of generating memory B cells having specificity for the Wuhan, Alpha, Epsilon, Gamma, or Beta variant of SARS-CoV2, the method comprising:
administering to a subject a recombinant vaccine composition in a prime and/or boost administration,
wherein the recombinant vaccine composition has a first portion encoding a severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein (N) that is fused to an endosomal targeting sequence (N-ETSD), wherein the first portion comprises a nucleic acid encoding the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:7,
wherein the first portion is functionally coupled to one or more regulatory elements that enable N-ETSD expression; and a second portion encoding a SARS virus spike protein (S),
wherein the second portion is functionally coupled to one or more regulatory elements that enable S expression; and
wherein the vaccine composition is administered in an amount that elicits generation of the memory B cells.